Local Institution

Mexico City, Mexico City 14080

0 studies enrolling now · 60 studies all time

What they study most

AIDS, Acute Ischemic Stroke, Advanced Solid Tumor, Albuminuria, Arthritis, Rheumatoid, Atrial Fibrillation, Atrial Flutter, Bipolar Disorder, Cancer of the Stomach, Carcinoma, Non-small Cell Lung Cancer, Chronic Hepatitis C Infection, Chronic Kidney Failure

Studies at this site

• A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis — Completed
• Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors — Completed
• A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib — Completed
• A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy — Withdrawn before enrolling
• Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV — Stopped early
• A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel — Completed
• An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets — Completed
• Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis — Completed
• Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate — Completed
• Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease — Stopped early
• Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder — Completed
• Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis — Completed
• Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin — Completed
• An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma — Withdrawn before enrolling
• Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation — Completed
• A Phase III Study of Apixaban in Patients With Atrial Fibrillation — Completed
• Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access — Completed
• Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes — Completed
• Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter — Stopped early
• A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer — Stopped early
• A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia — Completed
• A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker — Completed
• A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication — Completed
• Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer — Completed
• First Line Hepato Cellular Carcinoma (HCC) — Completed
• Study of Immunotherapy to Treat Advanced Prostate Cancer — Completed
• Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) — Completed
• Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer — Completed
• Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive — Stopped early
• Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness — Completed
• Methotrexate-Inadequate Response Study — Completed
• PoC in Rheumatoid Arthritis With Methotrexate — Completed
• Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 — Completed
• Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) — Completed
• Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis — Completed
• Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin — Completed
• A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise — Completed
• Phase IIIB Subcutaneous Missed Dose Study — Completed
• Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve) — Completed
• Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise — Completed
• Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis — Completed
• A Study of Abatacept in Patients With Active Ulcerative Colitis — Completed
• Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis — Stopped early
• Phase IIIB Switching From Intravenous to Subcutaneous Study — Completed
• Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone — Completed
• Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3) — Completed
• Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism — Completed
• Study of Aripiprazole in Patients With Acute Bipolar Mania — Completed
• A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control — Completed
• PPAR - Combination With Metformin — Completed